Glioblastoma (“GBM”)

VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

By | Glioblastoma ("GBM"), Press Releases
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology...
Read More

VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at the Immuno-Oncology Summit

By | Conferences, Glioblastoma ("GBM"), Press Releases
IND-enabling data, including restimulation of CMV-specific T-cell immunity in Rhesus Macaques Mechanistic data demonstrating VBI-1901 stimulates innate immunity Data presentation Wednesday, August 30, 2017 VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), today announced that David Anderson, Ph.D., Chief Scientific...
Read More